Spago Nanomedical AB (publ) (SPAGO.ST)
SEK 0.19
(7.39%)
SEK 0.19
(7.39%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.2 Million SEK | 14.14% |
| 2022 | 1.05 Million SEK | 59.7% |
| 2021 | 660 Thousand SEK | 92.98% |
| 2020 | 342 Thousand SEK | 1040.0% |
| 2019 | 30 Thousand SEK | -99.9% |
| 2018 | 29.64 Million SEK | 62972.34% |
| 2017 | 47 Thousand SEK | -18.97% |
| 2016 | 58 Thousand SEK | -99.23% |
| 2015 | 7.51 Million SEK | 13816.67% |
| 2014 | 54 Thousand SEK | -76.32% |
| 2013 | 228 Thousand SEK | 2.7% |
| 2012 | 222 Thousand SEK | -77.37% |
| 2011 | 981 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 350 Thousand SEK | -52.12% |
| 2024 Q2 | 459 Thousand SEK | 31.14% |
| 2023 Q2 | 114 Thousand SEK | 29.55% |
| 2023 Q3 | 271 Thousand SEK | 137.72% |
| 2023 FY | 1.2 Million SEK | 14.14% |
| 2023 Q4 | 731 Thousand SEK | 169.74% |
| 2023 Q1 | 88 Thousand SEK | -38.03% |
| 2022 FY | 1.05 Million SEK | 59.7% |
| 2022 Q1 | 211 Thousand SEK | 113.13% |
| 2022 Q4 | 142 Thousand SEK | -64.23% |
| 2022 Q3 | 397 Thousand SEK | 30.59% |
| 2022 Q2 | 304 Thousand SEK | 44.08% |
| 2021 Q3 | 195 Thousand SEK | -26.97% |
| 2021 Q1 | 100 Thousand SEK | -42.86% |
| 2021 Q4 | 99 Thousand SEK | -49.23% |
| 2021 Q2 | 267 Thousand SEK | 167.0% |
| 2021 FY | 660 Thousand SEK | 92.98% |
| 2020 FY | 342 Thousand SEK | 1040.0% |
| 2020 Q1 | 100 Thousand SEK | -96.14% |
| 2020 Q2 | 1.5 Million SEK | 1405.0% |
| 2020 Q3 | 67 Thousand SEK | -95.55% |
| 2020 Q4 | 175 Thousand SEK | 161.19% |
| 2019 Q2 | 30 Thousand SEK | -99.41% |
| 2019 Q4 | 2.59 Million SEK | -61.93% |
| 2019 Q3 | 6.8 Million SEK | 22576.67% |
| 2019 FY | 30 Thousand SEK | -99.9% |
| 2019 Q1 | 5.05 Million SEK | -41.22% |
| 2018 Q1 | 7.67 Million SEK | 18607.32% |
| 2018 Q3 | 6.71 Million SEK | 0.87% |
| 2018 Q4 | 8.59 Million SEK | 27.94% |
| 2018 FY | 29.64 Million SEK | 62972.34% |
| 2018 Q2 | 6.66 Million SEK | -13.17% |
| 2017 Q3 | 3.27 Million SEK | 6.3% |
| 2017 Q4 | 41 Thousand SEK | -98.75% |
| 2017 FY | 47 Thousand SEK | -18.97% |
| 2017 Q1 | 3000.00 SEK | -99.92% |
| 2017 Q2 | 3.07 Million SEK | 102533.33% |
| 2016 Q1 | 21 Thousand SEK | -98.58% |
| 2016 FY | 58 Thousand SEK | -99.23% |
| 2016 Q4 | 3.57 Million SEK | 9572.97% |
| 2016 Q3 | 37 Thousand SEK | -98.45% |
| 2016 Q2 | 2.38 Million SEK | 11271.43% |
| 2015 Q3 | 1.92 Million SEK | -14.62% |
| 2015 Q2 | 2.25 Million SEK | 20.5% |
| 2015 Q1 | 1.86 Million SEK | 31.64% |
| 2015 Q4 | 1.47 Million SEK | -23.31% |
| 2015 FY | 7.51 Million SEK | 13816.67% |
| 2014 FY | 54 Thousand SEK | -76.32% |
| 2014 Q4 | 1.41 Million SEK | 9360.0% |
| 2014 Q3 | 15 Thousand SEK | -61.54% |
| 2014 Q2 | 39 Thousand SEK | -98.52% |
| 2014 Q1 | 2.63 Million SEK | 263200.0% |
| 2013 Q1 | 138 Thousand SEK | 961.54% |
| 2013 Q3 | 30 Thousand SEK | -50.0% |
| 2013 Q4 | 1000.00 SEK | -96.67% |
| 2013 FY | 228 Thousand SEK | 2.7% |
| 2013 Q2 | 60 Thousand SEK | -56.52% |
| 2012 FY | 222 Thousand SEK | -77.37% |
| 2012 Q4 | 13 Thousand SEK | -93.78% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q3 | 209 Thousand SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2011 FY | 981 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 97.93% |
| Ziccum AB (publ) | 3.74 Million SEK | 67.894% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.805% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 97.617% |
| Mendus AB (publ) | 28.48 Million SEK | 95.777% |
| Genovis AB (publ.) | 158.23 Million SEK | 99.24% |
| Intervacc AB (publ) | 8.01 Million SEK | 84.991% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 72.497% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 99.294% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 97.259% |
| Aptahem AB (publ) | 2.63 Million SEK | 54.27% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -16.232% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -1462.338% |
| Fluicell AB (publ) | 3.33 Million SEK | 63.96% |
| Saniona AB (publ) | 16.84 Million SEK | 92.856% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 92.668% |
| Biovica International AB (publ) | 7.29 Million SEK | 83.498% |
| AcouSort AB (publ) | 10.55 Million SEK | 88.598% |
| Xintela AB (publ) | 78 Thousand SEK | -1442.308% |
| Abliva AB (publ) | 137 Thousand SEK | -778.102% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 97.911% |
| Karolinska Development AB (publ) | 2.01 Million SEK | 40.268% |
| OncoZenge AB (publ) | 3000.00 SEK | -40000.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -676.129% |
| CombiGene AB (publ) | 5.54 Million SEK | 78.301% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.9% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.93% |
| Corline Biomedical AB | 25.03 Million SEK | 95.194% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 78.813% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -66.852% |
| I-Tech AB | 120.86 Million SEK | 99.005% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 99.103% |
| Cyxone AB (publ) | 5.14 Million SEK | 76.632% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 82.936% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 88.72% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 89.288% |
| Nanologica AB (publ) | 1.44 Million SEK | 16.632% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -2169.811% |
| BioInvent International AB (publ) | 71.46 Million SEK | 98.317% |
| Alzinova AB (publ) | 270 Thousand SEK | -345.556% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 96.584% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 17.773% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | 57.371% |
| Simris Alg AB (publ) | 4.35 Million SEK | 72.37% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -825.385% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 99.496% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -5130.435% |